Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effects of PA-1 Transcriptional Regulation on Monocyte Function
This study is currently recruiting participants.
Verified by Vanderbilt University, August 2007
Sponsors and Collaborators: Vanderbilt University
National Institutes of Health (NIH)
Information provided by: Vanderbilt University
ClinicalTrials.gov Identifier: NCT00512369
  Purpose

Researching genetic differences in people with no prior medical conditions for better understanding of cardiac diseases through genetic research.


Condition
Atherosclerosis

U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Cross-Sectional, Defined Population, Prospective Study
Official Title: Angiotensin, the Vascular Endothelium, and Fibrinolysis - The Effects of PAI-1 Transcriptional Regulation on Human Monocyte Function

Further study details as provided by Vanderbilt University:

Estimated Enrollment: 125
Study Start Date: March 2006
Estimated Study Completion Date: March 2008
Detailed Description:

The discovery and subsequent application of small interfering RNA (siRNA) methods to achieve individual gene silencing in mammalian cells is a robust method that is well-described and validated in mammalian cell culture systems. We will apply this technique to achieve post-transcriptional "silencing" of PAI-1 in monocytes obtained from otherwise healthy volunteers, and study the subsequent loss of this gene's function on the migratory capacity of these cells in the proposed in vitro experimental system. This concept has not yet been demonstrated in the literature, and if validated, would be a novel and fundamental description of the role of PAI-1 in human monocyte biology as related to the development of atherosclerosis.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ages 18 -50
  • No current or past medical problems

Exclusion Criteria:

  • Patients taking prescription drugs (hormonal birth control or herbal supplements may be taken.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00512369

Contacts
Contact: Mohan Sathyamoorthy, ND 615-936-1719 mohan.sathyamoorthy@vanderbilt.edu

Locations
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Mohan Sathyamoorthy, MD     615-936-1719     mohan.saythya moorthy@vanderbilt.edu    
Sub-Investigator: Douglas E Vaughan, MD            
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Mohan Sathyamoorthy, MD Vanderbilt University
  More Information

Study ID Numbers: 060286, NIH
Study First Received: August 3, 2007
Last Updated: August 6, 2007
ClinicalTrials.gov Identifier: NCT00512369  
Health Authority: United States: Institutional Review Board;   United States: Food and Drug Administration

Keywords provided by Vanderbilt University:
Metabolic pathways
Atherosclerosis
Monocyte Function

Study placed in the following topic categories:
Arterial Occlusive Diseases
Atherosclerosis
Plasminogen Activator Inhibitor 1
Vascular Diseases
Arteriosclerosis

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 15, 2009